Filing Details
- Accession Number:
- 0001213900-14-006078
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-18 21:17:03
- Reporting Period:
- 2014-08-14
- Filing Date:
- 2014-08-18
- Accepted Time:
- 2014-08-18 21:17:03
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1503802 | Karyopharm Therapeutics Inc. | KPTI | Pharmaceutical Preparations (2834) | 263931704 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1591256 | Andreas Hadjimichael | Simou Menardou 8, Ria Court 8, Office 101 6015 Larnaca G4 | No | No | Yes | No | |
1591257 | Amalia Hadjimichael | Simou Menardou 8, Ria Court 8, Office 101 6015 Larnaca G4 | No | No | Yes | No | |
1591275 | Marcin Czernik | Simou Menardou 8, Ria Court 8, Office 101 6015 Larnaca G4 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-08-14 | 200 | $38.04 | 3,043,243 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2014-08-15 | 7,827 | $39.14 | 3,035,416 | No | 4 | S | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
Footnotes
- The prices reported in Column 4 are weighted average prices. The shares sold on 8/14/2014 were sold at prices ranging from $38.04 to $38.05, inclusive. The shares sold on 8/15/2014 were sold at prices ranging from $39.01 to $39.49, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Shares of Common Stock are owned directly by Plio Limited ("Plio"), which holds less than 10% of the outstanding Common Stock of the issuer. Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. Gregory Jankilevitsch , the sole shareholder of Plio, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. The shares owned by Plio do not include the 10,228,079 shares of the issuer's Common Stock held by Chione Limited, which has the same directors as Plio.
- Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
- Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.